TMG, also called betaine, appears in some NAD-related formulas and is often sold as an essential companion to NR or NMN. The rationale involves methyl groups used in metabolism.
A plausible mechanism is not enough to establish that every supplement user needs TMG. The useful question is whether human evidence shows a problem in the relevant setting and whether adding TMG improves a meaningful outcome.
There is no universal TMG requirement established by the evidence discussed here. Review the whole regimen and individual clinical context instead of adopting a fixed supplement ratio.
What is the concern being proposed?
Some NAD metabolism produces nicotinamide, whose breakdown can use methyl groups. That has prompted concern that high precursor intake might alter methyl-donor balance or homocysteine. It is a hypothesis to test, not a diagnosis that follows from buying an NR bottle. A biochemical pathway alone cannot tell an individual whether an extra supplement is needed.
What did NR-SAFE measure?
The 2023 NR-SAFE trial studied 20 people with Parkinson’s disease for four weeks, including a high-dose NR group. It did not find depletion of the whole-blood methyl-group pool. It did observe a mild serum homocysteine increase and a betaine decrease, with important distinctions between serum and whole-blood measurements. Those findings do not establish that all NR users must add TMG.
What the trial cannot settle
A short study in a specific patient group cannot determine every long-term effect or every person’s risk. It also was not a trial proving a universal TMG-to-NR ratio, nor a direct test of every NMN blend. The appropriate interpretation is limited reassurance about the measured setting, with unresolved questions. Do not turn its research amount into a home-use recommendation.
Why formulas include TMG anyway
Manufacturers can use a mechanistic rationale when designing combinations. Innerbody, for example, includes TMG alongside two precursors. That choice does not itself prove the combination is necessary or superior. Ask whether the finished formula has been compared with the same precursors without TMG and whether the difference affected an outcome that matters.
What to bring to a clinician or pharmacist
Bring the complete supplement and medication list, including B vitamins and other products marketed for methylation. If an abnormal laboratory result is the concern, discuss what it means in your own clinical context; do not self-diagnose methyl depletion from a symptom checklist. The interaction guide can help prepare a focused review.
How to evaluate an add-on offer
Ask which human study supports the claimed need, whether the proposed benefit is biochemical or clinical, and what would justify continuing. A stack can increase cost and complexity without making its contribution easier to assess. Compare the serving costs and read NR product differences before treating the add-on as mandatory.
Sources & reading notes
Editorial source review updated September 18, 2026. Provider pages describe their own offers; inclusion does not verify a product or its results.
- Berven et al. (2023): NR-SAFE Parkinson safety trial 20 participants, four weeks; short-term safety and metabolic observations, not long-term efficacy.
- Innerbody Labs: NAD+ Support Manufacturer page; related editorial content is not an independent comparison of its own product.
- NIH Office of Dietary Supplements: niacin Nutritional and biochemical context; not a clinical trial of NAD+ injections.
- FDA: questions and answers on dietary supplements Regulatory categories and limits of premarket review.
- FDA: mixing medications and dietary supplements General interaction and surgery guidance; specific risks must be matched to the actual ingredient and medication.
Educational information, not individualized medical advice. We do not claim medical review or firsthand treatment experience. Read our review standards and commercial disclosure.